| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| X4011 |
State-specific procedure code |
9,172 |
8,855 |
$2.17M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
5,586 |
5,413 |
$1.09M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
2,614 |
2,482 |
$708K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
6,909 |
6,637 |
$381K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
987 |
948 |
$372K |
| 80053 |
Comprehensive metabolic panel |
6,303 |
6,077 |
$322K |
| 81001 |
|
4,584 |
4,457 |
$278K |
| 71046 |
Radiologic examination, chest; 2 views |
1,006 |
979 |
$136K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
919 |
907 |
$130K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,153 |
1,124 |
$129K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
393 |
389 |
$126K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
395 |
127 |
$100K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
777 |
773 |
$92K |
| J3490 |
Unclassified drugs |
2,624 |
2,393 |
$81K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
409 |
408 |
$73K |
| 87081 |
|
1,882 |
1,872 |
$71K |
| 83690 |
|
1,051 |
1,023 |
$63K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
252 |
238 |
$58K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
764 |
760 |
$57K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
986 |
963 |
$56K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,318 |
1,292 |
$22K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
410 |
406 |
$22K |
| 81025 |
|
494 |
489 |
$21K |
| 71045 |
Radiologic examination, chest; single view |
314 |
307 |
$19K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
116 |
115 |
$15K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
237 |
231 |
$11K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
85 |
84 |
$10K |
| 84484 |
|
194 |
183 |
$7K |
| X4014 |
|
24 |
24 |
$7K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
86 |
86 |
$6K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
29 |
29 |
$6K |
| 80081 |
|
50 |
50 |
$6K |
| 84443 |
Thyroid stimulating hormone (TSH) |
187 |
187 |
$5K |
| 85379 |
|
26 |
24 |
$4K |
| 86803 |
|
64 |
64 |
$4K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
86 |
85 |
$3K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
40 |
40 |
$3K |
| 36415 |
Collection of venous blood by venipuncture |
763 |
738 |
$2K |
| Y7506 |
|
14 |
12 |
$1K |
| 83735 |
|
227 |
225 |
$898.62 |
| 87807 |
|
100 |
90 |
$863.41 |
| 83605 |
|
137 |
134 |
$738.48 |
| 85027 |
|
40 |
40 |
$230.39 |
| 87653 |
|
12 |
12 |
$134.75 |
| 80306 |
|
12 |
12 |
$90.57 |